At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 50 enrolled

Drug / intervention

Ranolazine +1 moredrug

Likely dose

Ranolazine 500mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02265796

NCT02265796Phase 2Completed

Compare CT.gov

Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients

North Florida Foundation for Research and Education·interventional·Posted Oct 16, 2014·Updated Aug 22, 2019

In Brief

A Phase 2 clinical trial evaluating Ranolazine and Sugar pill for Angina. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This is a prospective, double-blind, placebo-controlled, randomized, single-center (North Florida- South Georgia VA Medical Center) study. The study objective is to determine if ranolazine improves angina symptoms at 4 months compared with placebo among stable coronary artery disease patients who have demonstrable myocardial ischemia, but who do not undergo revascularization

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAngina

CountriesUnited States

CollaboratorsGilead Sciences

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartSep 2014

First PostedOct 2014

Primary CompletionMay 2016

Study CompletionSep 2016

TodayJul 2026

First PostedOct 16, 2014

Enrollment StartSep 1, 2014

Primary CompletionMay 1, 2016

Study CompletionSep 1, 2016

TodayJul 2, 2026

Enrollment to primary: 1.7 yearsPosted 11.7 years ago

Interventions

Ranolazinedrug

Ranolazine 500mg tablet 1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks

Sugar pilldrug

1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks